TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6691784
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy and Pharmacotherapy (N = 28)
Study: 31064968
Drug: Oral cryotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cryotherapy during chemotherapy
Study: 28620848
Drug: Standard-of-Care (SoC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-Care (SoC) platinum-based chemotherapy
Study: 23798725
Drug: telcagepant 600
Normalized name: Telcagepant
DrugBank: Telcagepant (DB12228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: telcagepant 600 mg
Study: 23798725
Drug: telcagepant 600
Normalized name: Telcagepant
DrugBank: Telcagepant (DB12228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: telcagepant 600 mg with sumatriptan 100 mg
Study: 19208459
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (arformoterol 15microg BID and tiotropium 18microg QD)
Study: 11131273
Drug: Lisinopril 10-20
Normalized name: lisinopril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 10-20 mg daily for 8 weeks
Study: 11131273
Drug: Nitrendipine 5-10
Normalized name: nitrendipine
DrugBank: Nitrendipine (DB01054)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine 5-10 mg daily for 8 weeks
Study: 11131273
Drug: Nitrendipine 5-10
Normalized name: nitrendipine
DrugBank: Nitrendipine (DB01054)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine 5-10 mg daily for 8 weeks followed by Lisinopril 10-20 mg daily for another 8 weeks
Study: 1606777
Drug: rHuEpo 40
Normalized name: GlycoPEGylated™rHuEPO
DrugBank: NE-180 (DB05619)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuEpo 40 U/kg intravenously three times weekly (Group 1)
Study: 1606777
Drug: rHuEpo 40
Normalized name: GlycoPEGylated™rHuEPO
DrugBank: NE-180 (DB05619)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuEpo 40 U/kg intravenously three times weekly with nandrolone decanoate 2 mg/kg weekly (Group 2)
Study: 2832549
Drug: Cisplatin 20
Normalized name: CISPLATIN 200MG/VIL (PF) INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 20 mg/m2 X 4 plus etoposide (VP‐16) 100 mg/m2 X 4 every 4 weeks for two courses
Study: 28597226
Drug: AL 441
Normalized name: Al
DrugBank: Aluminium (DB01370)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AL 441 mg q4wk
Study: 28597226
Drug: AL 882
Normalized name: Al
DrugBank: Aluminium (DB01370)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AL 882 mg q6wk
Study: 28597226
Drug: AL 1064
Normalized name: Al
DrugBank: Aluminium (DB01370)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AL 1064 mg q8wk
Study: 12687595
Drug: High-dose aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose aerosol beclomethasone (2.40-3.69 microg/kg/day)
Study: 12687595
Drug: Medium-dose aerosol
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose aerosol beclomethasone (1.0-1.85 microg/kg/day)
Study: 12687595
Drug: Low-dose aerosol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose aerosol beclomethasone (0.48-0.74 microg/kg/day)
Study: 8642081
Drug: 25% glycolic,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% glycolic, lactic, or citric acid lotion
Study: 28337945
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy integrated with motivational interviewing (MI-CBT)
Study: 28337945
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy alone (CBT)
Study: 27080115
Drug: Ibuprofen/Paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen/Paracetamol
Study: 27080115
Drug: Diclofenac K/Paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac K/Paracetamol
Study: 27080115
Drug: Mefenamic Acid/Paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefenamic Acid/Paracetamol
Study: 20434544
Drug: Two-dose regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-dose regimen of combined hepatitis A and B vaccine (0, 6 months, Adult formulation)
Study: 20434544
Drug: Three-dose regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-dose regimen of combined hepatitis A and B vaccine (0, 1, 6 months, Paediatric formulation)
Study: 20434544
Drug: Challenge dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Challenge dose of hepatitis B vaccine administered to subjects with anti-HBs antibody concentration < or =10mIU/mL
Study: 18300356
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy with lamivudine-IFN-alpha 2b for 48 weeks
Study: 18300356
Drug: Lamivudine monotherapy
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine monotherapy for 48 weeks
Study: 18300356
Drug: IFN-alpha 2b
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IFN-alpha 2b monotherapy for 24 weeks
Study: 18300356
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with sustained virological response after 24 weeks of therapy withdrawal
Study: 16231260
Drug: Continuous fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous fluconazole (200 mg 3 times weekly)
Study: 11249886
Drug: Aggressive strategy
Normalized name: ZO SKIN HEALTH Aggressive Anti-Aging Program KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive strategy (maximum burr/artery >0.70 with adjunctive balloon inflation < or = 1 atm)
Study: 7988775
Drug: Polymorphisms in
Normalized name: Murine MAb to polymorphic epithelial mucin, human milk fat globule 1
DrugBank: Pemtumomab (DB18563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polymorphisms in the insulin gene region in Caucasians
Study: 7988775
Drug: Polymorphisms in
Normalized name: Murine MAb to polymorphic epithelial mucin, human milk fat globule 1
DrugBank: Pemtumomab (DB18563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polymorphisms in the insulin gene region in Tanzanian blacks
Study: 7988775
Drug: Polymorphisms in
Normalized name: Murine MAb to polymorphic epithelial mucin, human milk fat globule 1
DrugBank: Pemtumomab (DB18563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polymorphisms in the insulin gene region in Japanese orientals
Study: 31624941
Drug: Same-day dose
Normalized name: SAMe
DrugBank: Ademetionine (DB00118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same-day dose (SDD) of polyethylene glycol (PEG) starting at 7 AM on the day of colonoscopy
Study: 31624941
Drug: Split dose
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split dose (SPD) of polyethylene glycol (PEG) - 2 L at 9 PM the day before and 2 L from 10 AM on the day of colonoscopy
Study: 31624941
Drug: Same-day dose
Normalized name: SAMe
DrugBank: Ademetionine (DB00118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same-day dose (SDD)
Study: 31624941
Drug: Split dose
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split dose (SPD)
Study: 28102979
Drug: Present‐centered therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Present‐centered therapy
Study: 19459427
Drug: Losartan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (50 mg/day) with indapamide (1.5 mg/day)
Study: 11473038
Drug: gliclazide (40-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: gliclazide (40-80 mg twice daily for 5 weeks)
Study: 11473038
Drug: gliclazide (acute
Approvals — FDA: no, EMA: no, PMDA: no
Description: gliclazide (acute treatment)
Study: 11473038
Drug: gliclazide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: gliclazide (5 weeks treatment)
Study: 8066559
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (800 micrograms beclomethasone daily)
Study: 8066559
Drug: Bronchodilators only
Normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bronchodilators only (control group)
Study: 28804807
Drug: Corticotropin-releasing hormone
Normalized name: corticotropin-releasing hormone
DrugBank: Corticorelin (DB05394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticotropin-releasing hormone (CRH) injection
Study: 28804807
Drug: NaCl (placebo)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl (placebo) injection
Study: 21283543
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy without Atorvastatin
Study: 19255328
Drug: AZA 5-2-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZA 5-2-2 (75 mg/m(2)/d for 5 days, then 2 days no treatment, then 75 mg/m(2)/d for 2 days)
Study: 19255328
Drug: AZA 5-2-5
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZA 5-2-5 (50 mg/m(2)/d for 5 days, then 2 days no treatment, then 50 mg/m(2)/d for 5 days)
Study: 19255328
Drug: AZA 5
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AZA 5 (75 mg/m(2)/d for 5 days)
Study: 16109807
Drug: Irbesartan (AT1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan (AT1 receptor blocker)
Study: 15120009
Drug: Budesonide inhaled
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide inhaled from Easyhaler (Giona Easyhaler)
Study: 15120009
Drug: Budesonide inhaled
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide inhaled from Turbuhaler (Pulmicort Turbuhaler)
Study: 15120009
Drug: Budesonide inhaled
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide inhaled from Turbuhaler
Study: 15120009
Drug: Budesonide inhaled
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide inhaled from Easyhaler
Study: 10943876
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral methotrexate (MTX)
Study: 2180405
Drug: Daily auranofin
Normalized name: Auranofin
DrugBank: Auranofin (DB00995)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily auranofin (AUR)
Study: 395523
Drug: Danazol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danazol (400 mg daily for 2 months)
Study: 25865966
Drug: Blond orange
Normalized name: Orange
DrugBank: Orange (DB10549)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blond orange juice (200 mL, 3 times daily for 4 weeks)
Study: 25865966
Drug: Control beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control beverage (200 mL, 3 times daily for 4 weeks)
Study: 24877717
Drug: Glucevia(®) (333
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucevia(®) (333 mg per capsule, 3 capsules daily for 3 weeks)
Study: 22038507
Drug: Glutamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamine (0.5 g/kg ideal body weight/day for 2 months)
Study: 22038507
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein (0.5 g/kg ideal body weight/day for 2 months)
Study: 20226365
Drug: Conventional conservative
Normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional conservative therapy (CCT)
Study: 16257842
Drug: Epoetin-alpha (aiming
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoetin-alpha (aiming for hemoglobin level 135-160 g/l)
Study: 12153826
Drug: Risperidone (0.02-0.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (0.02-0.06 mg/kg per day)
Study: 8651966
Drug: IVIg (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIg (5 mg/kg)
Study: 7996367
Drug: Albumin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albumin (5 mg/kg)
Study: 29669026
Drug: Modified vaccinia
Normalized name: Modified vaccinia ankara
DrugBank: Modified vaccinia ankara (DB15483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified vaccinia Ankara (MVA)-vectored HIV-1 bivalent mosaic immunogen vaccine
Study: 29669026
Drug: Prototype Ad26.ENVA.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prototype Ad26.ENVA.01 vaccine
Study: 28848908
Drug: Formoterol fumarate
Normalized name: Formoterol Fumarate
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Formoterol fumarate delivered by metered dose inhaler (MDI) at doses of 7.2, 9.6, and 19.2 micrograms
Study: 28848908
Drug: Formoterol fumarate
Normalized name: Formoterol Fumarate
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Formoterol fumarate delivered by metered dose inhaler (MDI) at 9.6 micrograms
Study: 16408815
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 600 mg fudosteine
Study: 16408815
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 400 mg fudosteine
Study: 16408815
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 200 mg fudosteine
Study: 16408815
Drug: Multiple dose
Normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dose of 400 mg fudosteine (3 times a day for 5 days)
Study: 9737803
Drug: Intramuscular soluble
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular soluble insulin
Study: 9737803
Drug: Subcutaneous soluble
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous soluble insulin
Study: 9737803
Drug: Intramuscular insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular insulin lispro
Study: 15336577
Drug: Subcutaneous insulin
Normalized name: subcutaneous insulin pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous insulin lispro
Study: 2221971
Drug: Lowest plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lowest plasma prolactin concentrations (<1000 mU/l, 32.9 micrograms/l)
Study: 350145
Drug: Karminomycin 5
Normalized name: dactinomycin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Karminomycin 5 mg/m2 daily for 5 days
Study: 350145
Drug: Karminomycin 6
Normalized name: Dactinomycin
DrugBank: Dactinomycin (DB00970)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Karminomycin 6 mg/m2 twice a week for 2-3 weeks
Study: 21784529
Drug: BDP‐HFA 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDP‐HFA 100 μg BID
Study: 21784529
Drug: BDP‐CFC 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDP‐CFC 200 μg BID
Study: 21784529
Drug: BDP‐HFA 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDP‐HFA 100 μg BID and BDP‐CFC 200 μg BID
Study: 19351812
Drug: Weekly physical
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly physical therapy
Study: 19351812
Drug: Monthly physical
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly physical therapy
Study: 16879975
Drug: Cycle HRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cycle HRT schedule (0.625 mg conjugated estrogen from days 1 to 28 + 5 mg medroxyprogesterone acetate from days 18 to 28) for 2 months (n=25)
Study: 16879975
Drug: Continue HRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continue HRT schedule (0.625 mg conjugated estrogen + 2.5 mg medroxyprogesterone acetate from days 1 to 28) for 2 months (n=25)
Study: 9227252
Drug: 89Sr chloride
Normalized name: strontium chloride, 89Sr-labeled
DrugBank: Strontium chloride Sr-89 (DB09498)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 89Sr chloride therapy
Study: 25044799
Drug: lorcaserin 10
Normalized name: lorcaserin 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: lorcaserin 10 mg bid
Study: 18384230
Drug: Continue neuroleptic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continue neuroleptic treatment for 12 months
Study: 18384230
Drug: Placebo (discontinue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (discontinue treatment)
Study: 15690237
Drug: Prednisolone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (30 mg/kg) added to the priming solution of the cardiopulmonary bypass circuit
Study: 15690237
Drug: No steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: No steroids (nonsteroid group)
Study: 7551381
Drug: Nutritional intervention
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional intervention (420 kcal daily high caloric supplement)
Study: 7551381
Drug: Nutritional intervention
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional intervention + Nandrolone decanoate (25 mg for women, 50 mg for men, injected intramuscularly on Days 1, 15, 29, and 43)
Study: 30880937
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment for COPD exacerbation
Study: 15570142
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g of casein (CS)
Study: 9135492
Drug: Epirubicin 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin 60 mg/m2/24 h (total dose for cycle 180 mg/m2) days 1, 2 and 3 (group A)
Study: 9135492
Drug: Epirubicin 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin 60 mg/m2/24 h days 1, 2 and 3 and cisplatin 30 mg/m2/24 h days 2, 3, 4 and 5 (group B)
Study: 16428570
Drug: 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg lidocaine + 8 mg dexamethasone
Study: 16428570
Drug: 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg lidocaine
Study: 16428570
Drug: 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg lidocaine for IVRA and 8 mg dexamethasone IV to the nonsurgical arm
Study: 9354316
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg once daily for 3 days
Study: 9354316
Drug: Placebo once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily for 3 days
Study: 17944274
Drug: Live, attenuated
Normalized name: Ebola Zaire vaccine (live, attenuated)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live, attenuated intranasal influenza vaccine
Study: 17944274
Drug: Novel inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel inhibitors for influenza, RSV, and rhinovirus infections
Study: 17944274
Drug: Antiviral therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral therapies and vaccine strategies
Study: 11268947
Drug: MFL (Methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: MFL (Methotrexate 100 mg/m2 and 5-FU 600 mg/m2 followed by leucovorin rescue)
Study: 11268947
Drug: UFT-MMC (Mitomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT-MMC (Mitomycin C 12 mg/m2 intraoperatively and 6 mg/m2 every other week for 2 months, oral UFT 375 mg/m2/day for 3 years or longer)
Study: 9917606
Drug: Cementless taper
Normalized name: caper berry extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cementless taper design femoral components
Study: 9917606
Drug: Cemented femoral
Normalized name: Sus scrofa temporal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cemented femoral implants
Study: 7819596
Drug: Intravenous immunoglobulins
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulins (100 mg/kg)
Study: 7819596
Drug: Intravenous immunoglobulins
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulins (250 mg/kg)
Study: 7819596
Drug: Intravenous immunoglobulins
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulins (400 mg/kg)
Study: 3278367
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g apple pectin USP powder twice daily
Study: 3278367
Drug: One tablet
Normalized name: Hydone Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet matching ranitidine placebo at night
Study: 31359829
Drug: Romiplostim administration
Normalized name: Romiplostim
DrugBank: Romiplostim (DB05332)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Romiplostim administration after transplantation
Study: 23778995
Drug: Control (conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (conventional systemic therapy)
Study: 17058828
Drug: Ginaton 1
Normalized name: Genaton
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginaton 1 mg/kg by intravenous dripping before open heart for CPB
Study: 10720289
Drug: Cladribine 0.07
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cladribine 0.07 mg/kg/day for 5 consecutive days every 4 weeks for two cycles (total dose 0.7 mg/kg)
Study: 10720289
Drug: Cladribine 0.07
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cladribine 0.07 mg/kg/day for 5 consecutive days every 4 weeks for six cycles (total dose 2.1 mg/kg)
Study: 8645512
Drug: Omeprazole: an
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole: an initial bolus of 80 mg + perfusion of 3.3 mg/h
Study: 8645512
Drug: Omeprazole: an
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole: an initial bolus of 80 mg + 40 mg/12 h
Study: 8645512
Drug: Omeprazole: 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole: 40 mg/8 h
Study: 8645512
Drug: Ranitidine: perfusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine: perfusion of 12.5 mg/h
Study: 8645512
Drug: Ranitidine: 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine: 50 mg/4 h
Study: 19684633
Drug: Total body
Normalized name: Total Body Massager Item
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total body MRI-governed involved compartment irradiation (ICI) followed by high-dose chemotherapy (HDC) and stem cell rescue (SCR)
Study: 15925814
Drug: PEFG regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEFG regimen (40 mg/m2 cisplatin, 40 mg/m2 epirubicin, 600 mg/m2 gemcitabine, 200 mg/m2 fluorouracil)
Study: 15925814
Drug: Gemcitabine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine alone (1000 mg/m2)
Study: 12689974
Drug: Interleukin-2 receptor
Normalized name: Interleukin-2 receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin-2 receptor antibodies
Study: 10646047
Drug: Racecadotril (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Racecadotril (100 mg three times daily)
Study: 10646048
Drug: Loperamide (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide (2 mg after each diarrhoeic stool)
Study: 7201837
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg antipyrine (phenazone) administered intravenously (i.v.)